Advancing siRNA Drug Discovery and Development with AI
Published March 14, 2025
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully achieved, marking a significant leap forward in Ribo's AI-assisted drug development for RNA therapeutics.
Leveraging Pheiron’s advanced AI platform, PheironGPS, multiple candidate targets have systematically been profiled by integrating large-scale human multi-omic data with cutting-edge AI analytics.
This collaboration underscores our joint commitment to implementing AI-analysis of large-scale human biomedical data to transform drug development, setting new benchmarks for innovation in the biotech and pharmaceutical sectors.
“We are really impressed by the team at Pheiron and the PheironGPS platform and we are excited to continue the collaboration to build in-depth patient genetic, biomarker and phenotypic characterization for our target prioritization and clinical R&D path. A new phase of AI-guided clinical development R&D is indeed here.”
— Anders Gabrielsen, Global Head Clinical Development, Ribocure Pharmaceuticals
“We are excited to continue our collaboration with the stellar team at Ribocure and continue our collaboration around advancing the next-generation RNA therapeutics. We are the first generation to measure human biology in depth and at scale and as human biomedical data becomes abundantly available, we have an unprecedented opportunity to root decisions in human-level evidence to move faster, de-risk translation, and increase probability of program success.”
— Thore Buergel, CEO, Pheiron
Pheiron
Pheiron is an AI-native tech-bio company specializing in phenotypic disease characterization and genetic evidence. Its platform, PheironGPS, integrates the largest and best-characterized human datasets to generate actionable insights on disease biology. Pheiron supports the identification and prioritization of high-impact therapeutic targets, helps stratify patient populations, and optimizes clinical-stage asset positioning. For more information about Pheiron, please contact Thore Buergel, CEO, at thore.buergel@pheiron.com.
Suzhou Ribo Life Science Ltd, and Ribocure Pharmaceuticals
Suzhou Ribo Life Science Ltd is a clinical-stage biotech company in the field of cutting-edge RNA therapeutics. Ribocure Pharmaceuticals AB is the international research Center of Suzhou Ribo Life Science. Ribo’s mission is to establish a world-leading RNA research and development company, ultimately positively impacting patients worldwide. For more information, please contact Julia Grönros, Project Director External Innovation, at julia.gronros@ribocure.com.
